Pfizer INLYTA oral therapy wins European marketing authorization
INLYTA, a kinase inhibitor, is designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2 and 3,1a, which are proteins that influence tumor growth, vascular angiogenesis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.